Literature DB >> 34035503

Cemiplimab is a new option in BCC.

Diana Romero1.   

Abstract

Entities:  

Year:  2021        PMID： 34035503     DOI： 10.1038/s41571-021-00528-7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

Authors:  Alexander J Stratigos; Aleksandar Sekulic; Ketty Peris; Oliver Bechter; Sorilla Prey; Martin Kaatz; Karl D Lewis; Nicole Basset-Seguin; Anne Lynn S Chang; Stèphane Dalle; Almudena Fernandez Orland; Lisa Licitra; Caroline Robert; Claas Ulrich; Axel Hauschild; Michael R Migden; Reinhard Dummer; Siyu Li; Suk-Young Yoo; Kosalai Mohan; Ebony Coates; Vladimir Jankovic; Nathalie Fiaschi; Emmanuel Okoye; Ioannis D Bassukas; Carmen Loquai; Vincenzo De Giorgi; Zeynep Eroglu; Ralf Gutzmer; Jens Ulrich; Susana Puig; Frank Seebach; Gavin Thurston; David M Weinreich; George D Yancopoulos; Israel Lowy; Timothy Bowler; Matthew G Fury
Journal:  Lancet Oncol       Date:  2021-05-14       Impact factor: 41.316
  1 in total
  2 in total

Review 1.  Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors:  Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

2.  Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: a Retrospective Study.

Authors:  Florian Herms; Barouyr Baroudjian; Julie Delyon; Pauline Laly; Pauline Tetu; Celeste Lebbe; Nicole Basset-Seguin
Journal:  Acta Derm Venereol       Date:  2022-05-23       Impact factor: 3.875
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.